Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0074 | 0.4656 | 0.7318 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0097 | 0.6363 | 1 |
Brugia malayi | triosephosphate isomerase | 0.0097 | 0.6363 | 0.6187 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Schistosoma mansoni | triosephosphate isomerase | 0.0039 | 0.1955 | 0.3073 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0074 | 0.4656 | 0.6639 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3186 | 0.5008 |
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0097 | 0.6363 | 1 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.1286 | 0.0866 |
Chlamydia trachomatis | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Leishmania major | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Echinococcus granulosus | proteasome prosome macropain | 0.0074 | 0.4656 | 0.7318 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0097 | 0.6363 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0074 | 0.4656 | 0.7318 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0074 | 0.4656 | 0.6639 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5826 |
Schistosoma mansoni | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.3186 | 0.218 |
Trypanosoma brucei | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3186 | 0.5008 |
Plasmodium falciparum | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Treponema pallidum | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.3186 | 0.2858 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.3186 | 0.5008 |
Plasmodium falciparum | triosephosphate isomerase, putative | 0.0039 | 0.1955 | 0.1318 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0039 | 0.1955 | 0.1318 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.0074 | 0.4656 | 0.4399 |
Echinococcus granulosus | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0097 | 0.6363 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0074 | 0.4656 | 0.3868 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.3186 | 0.5008 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0074 | 0.4656 | 0.6639 |
Entamoeba histolytica | triosephosphate isomerase | 0.0097 | 0.6363 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.3186 | 0.5008 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0074 | 0.4656 | 0.6639 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0097 | 0.6363 | 1 |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0097 | 0.6363 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. qHTS for Inhibitors of TGF-b: Confirmation of Cherry Picks. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PubChem BioAssay. qHTS for Inhibitors of TGF-b: Hit Validation in HepG2 Cells using COP promoter. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.